Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Alopecia Wigs Insurance topic
No spam. Unsubscribe anytime.
Mass. hearing presses insurers to cover wigs, scalp and facial prostheses for alopecia patients
Summary
Patients, clinicians and legislators urged the Joint Committee on Financial Services to advance bills (S832/H1223) that would require insurers to cover scalp and facial hair prostheses for people with alopecia areata, citing low per‑policy cost estimates and substantial mental‑health and quality‑of‑life impacts.
Heidi Bratt, a longtime advocate who has lived with alopecia areata for decades, told the Joint Committee on Financial Services that bills S832 and H1223 would require insurers in Massachusetts to pay for medically necessary hair prostheses for people with the autoimmune condition. “I have had alopecia areata for over 40 years,” Bratt said in her testimony, describing repeated attempts to secure coverage and calling denial of access “discriminatory.”
Representative Sally Kearns and Senators Joan Lovely and Bruce Tarr joined patients and clinicians in urging the committee to move the measure forward. Kearns summarized earlier analysis by the Center for Health Information and Analysis (CHIA), saying prior work found the per‑policy cost to be negligible. Senator Lovely noted a CHIA figure cited in committee discussion that individual rate‑payer impact had been estimated in prior reviews at under 10¢ per year in one instance and described the measure as an insurance mandate that should be re‑assessed with an updated CHIA study.
Clinical witnesses framed prostheses as medically meaningful rather than cosmetic. Dr. Arash Mosagimi, a dermatologist at Brigham and Women’s Hospital, described alopecia’s mental‑health effects and said that while new FDA‑approved drugs can help some patients, they are costly and not effective or appropriate for everyone; for many, a prosthetic wig is a reliable option to preserve functioning and social participation. Medical‑student researcher Samantha Gregoire told the committee that a recent survey of 500 patients found the average patient spent about $1,900 on alopecia‑related costs over six months, with wigs the largest driver.
Members pressed witnesses on details of prior CHIA work and on potential cost and scope. Supporters said the bills include medical‑necessity criteria and would require clinician verification; they asked the committee to refer the measure to healthcare finance for updated fiscal analysis. Opponents were not prominent in the hearing record for this item; committee chairs encouraged additional written testimony and technical work before any final vote.
The committee did not take a vote on the bills at the hearing; sponsors asked members to pursue further analysis and a committee referral.
